CDK9

Class

Small molecule CDK9 inhibitor

Pathway

Transcriptional regulation via RNA Pol II CTD phosphorylation blockade, downregulating short-lived anti-apoptotic proteins (e.g. MCL-1)

CDK9 is a cyclin-dependent kinase that partners with cyclin T1 to form a complex called P-TEFb (positive transcription elongation factor b). Its job is to phosphorylate the C-terminal domain of RNA polymerase II, the enzyme that transcribes DNA into messenger RNA. This phosphorylation releases polymerase from a paused state at the start of genes and allows it to elongate transcripts efficiently. Because CDK9 activity is required continuously for active transcription, blocking it has a disproportionate effect on genes encoding proteins with very short half-lives, since their supply depends on constant new transcription. Several proteins that help cancer cells resist programmed cell death, notably MCL-1, fall into this category. By suppressing CDK9-driven transcription, inhibitors reduce the pool of these survival proteins faster than longer-lived proteins are affected, tipping malignant cells toward apoptosis. This mechanism is of particular interest in blood cancers and other tumors that depend heavily on such short-lived survival factors to escape cell death. As a strategy, it targets transcriptional output rather than a single mutated oncogene, offering an approach applicable across tumor types that share this dependency rather than a specific genetic alteration.